Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment Trial.
Schlenk
R F
RF
Fröhling
S
S
Hartmann
F
F
Fischer
J Th
JT
Glasmacher
A
A
Del Valle
F
F
Götze
K
K
Nerl
C
C
Schoch
R
R
Pralle
H
H
Mergenthaler
H G
HG
Hensel
M
M
Koller
E
E
Kirchen
H
H
Matzdorff
A
A
Salwender
H
H
Biedermann
H G
HG
Kremers
S
S
Haase
D
D
Benner
A
A
Döhner
K
K
Döhner
H
H
D000208:Acute Disease; D000284:Administration, Oral; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D007275:Injections, Intravenous; D007951:Leukemia, Myeloid / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012074:Remission Induction; D015996:Survival Rate; D016896:Treatment Outcome; D014212:Tretinoin / Q000008:administration & dosage
D014212:Tretinoin; D005047:Etoposide; D015255:Idarubicin